Home/Filings/4/0001737287-25-000020
4//SEC Filing

Douglas Earl Martin 4

Accession 0001737287-25-000020

CIK 0001737287other

Filed

Feb 4, 7:00 PM ET

Accepted

Feb 5, 4:16 PM ET

Size

5.0 KB

Accession

0001737287-25-000020

Insider Transaction Report

Form 4
Period: 2025-02-03
Douglas Earl Martin
SVP, General Counsel
Transactions
  • Sale

    Common Stock

    2025-02-03$1.71/sh6,404$10,951587,848 total
Footnotes (1)
  • [F1]Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Issuer

Allogene Therapeutics, Inc.

CIK 0001737287

Entity typeother

Related Parties

1
  • filerCIK 0001362155

Filing Metadata

Form type
4
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 4:16 PM ET
Size
5.0 KB